Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and ...

Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in ...

As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a ...

The combination of Merck's Welireg and Eisai's Lenvima has not yet shown statistical significance in extending overall ...

Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and ...

A phase 2 trial supports SBRT for primary treatment of localized RCC. Stereotactic body radiotherapy (SBRT) showed favorable long-term local control and cause-specific survival (CSS) in a phase 2 ...

Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer ...

A study from the University of Michigan Health Rogel Cancer Center and Department of Pathology shows that further testing in ...

At the molecular level, transcriptomic profiling of a single nucleus RNA-seq dataset of renal epithelial cells revealed ...

Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows ...

Sweis, MD, and participants discussed their impressions of combination trials in non–clear cell renal cell carcinoma.

Retired Tennessee football mascot Smokey X has been diagnosed with kidney cancer according to the University of Tennessee ...